## Tore Skotland

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5518033/tore-skotland-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67
papers

4,187
citations

26
h-index

9-index

70
ext. papers

5,044
ext. citations

6.5
avg, IF

L-index

#	Paper	IF	Citations
67	Are doping tests in sports trustworthy?: Athletes suffer from insufficiently defined criteria for doping tests: Athletes suffer from insufficiently defined criteria for doping tests <i>EMBO Reports</i> , <b>2022</b> , e54431	6.5	1
66	Need for more focus on lipid species in studies of biological and model membranes <i>Progress in Lipid Research</i> , <b>2022</b> , 101160	14.3	1
65	Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges <i>Advanced Drug Delivery Reviews</i> , <b>2022</b> , 114326	18.5	1
64	Modulation of Ricin Intoxication by the Autophagy Inhibitor EACC. <i>Toxins</i> , <b>2022</b> , 14, 360	4.9	
63	Diacylglycerol kinase and phospholipase D inhibitors alter the cellular lipidome and endosomal sorting towards the Golgi apparatus. <i>Cellular and Molecular Life Sciences</i> , <b>2021</b> , 78, 985-1009	10.3	3
62	Biodistribution of Poly(alkyl cyanoacrylate) Nanoparticles in Mice and Effect on Tumor Infiltration of Macrophages into a Patient-Derived Breast Cancer Xenograft. <i>Nanomaterials</i> , <b>2021</b> , 11,	5.4	4
61	Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells. <i>Nanotoxicology</i> , <b>2021</b> , 15, 865-884	5.3	1
60	The Protein Toxins Ricin and Shiga Toxin as Tools to Explore Cellular Mechanisms of Internalization and Intracellular Transport. <i>Toxins</i> , <b>2021</b> , 13,	4.9	3
59	Transport of nanoparticles across the endothelial cell layer. <i>Nano Today</i> , <b>2021</b> , 36, 101029	17.9	11
58	Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells. <i>International Journal of Pharmaceutics</i> , <b>2021</b> , 597, 120217	6.5	4
57	An emerging focus on lipids in extracellular vesicles. <i>Advanced Drug Delivery Reviews</i> , <b>2020</b> , 159, 308-32	<b>21</b> 18.5	134
56	Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer. <i>Biomacromolecules</i> , <b>2020</b> , 21, 1489-1498	6.9	24
55	The role of lipid species in membranes and cancer-related changes. <i>Cancer and Metastasis Reviews</i> , <b>2020</b> , 39, 343-360	9.6	17
54	Structural Variants of poly(alkylcyanoacrylate) Nanoparticles Differentially Affect LC3 and Autophagic Cargo Degradation. <i>Journal of Biomedical Nanotechnology</i> , <b>2020</b> , 16, 432-445	4	4
53	Physicochemical Characterization, Toxicity and Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin. <i>Journal of Biomedical Nanotechnology</i> , <b>2020</b> , 16, 419-431	4	2
52	Biological response and cytotoxicity induced by lipid nanocapsules. <i>Journal of Nanobiotechnology</i> , <b>2020</b> , 18, 5	9.4	12
51	Mass spectrometry-based measurements of cyclic adenosine monophosphate in cells, simplified using reversed phase liquid chromatography with a polar characterized stationary phase. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2020</b> , 1160, 122384	3.2	O

50	The role of PS 18:0/18:1 in membrane function. <i>Nature Communications</i> , <b>2019</b> , 10, 2752	17.4	31
49	Improving scientific practice in sports-associated drug testing. FEBS Journal, 2019, 286, 2664-2669	5.7	2
48	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 370, 581-59	<b>2</b> 1·7	35
47	Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. Journal of Lipid Research, <b>2019</b> , 60, 9-18	6.3	231
46	Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy. <i>International Journal of Nanomedicine</i> , <b>2019</b> , 14, 6269-6285	7.3	12
45	Small variations in nanoparticle structure dictate differential cellular stress responses and mode of cell death. <i>Nanotoxicology</i> , <b>2019</b> , 13, 761-782	5.3	16
44	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft. <i>Journal of Controlled Release</i> , <b>2019</b> , 293, 183-192	11.7	22
43	Clathrin-independent endocytosis: an increasing degree of complexity. <i>Histochemistry and Cell Biology</i> , <b>2018</b> , 150, 107-118	2.4	95
42	Exogenous lysophospholipids with large head groups perturb clathrin-mediated endocytosis. <i>Traffic</i> , <b>2017</b> , 18, 176-191	5.7	9
41	Doping and drug testing: Anti-doping work must be transparent and adhere to good scientific practices to ensure public trust. <i>EMBO Reports</i> , <b>2017</b> , 18, 351-354	6.5	6
40	Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers. <i>European Journal of Cancer</i> , <b>2017</b> , 70, 122-132	7.5	176
39	Lipids in exosomes: Current knowledge and the way forward. <i>Progress in Lipid Research</i> , <b>2017</b> , 66, 30-41	14.3	495
38	Injection of nanoparticles into cloven-hoof animals: Asking for trouble. <i>Theranostics</i> , <b>2017</b> , 7, 4877-4878	12.1	9
37	Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 98, 80-85	5.1	53
36	Cytotoxicity of Poly(Alkyl Cyanoacrylate) Nanoparticles. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	26
35	Protection against Shiga Toxins. <i>Toxins</i> , <b>2017</b> , 9,	4.9	37
34	Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide. <i>Oncotarget</i> , <b>2017</b> , 8, 76921-76934	3.3	9
33	Addition of lysophospholipids with large head groups to cells inhibits Shiga toxin binding. <i>Scientific Reports</i> , <b>2016</b> , 6, 30336	4.9	9

32	Interdigitation of long-chain sphingomyelin induces coupling of membrane leaflets in a cholesterol dependent manner. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>2016</b> , 1858, 281-8	3.8	61
31	Cellular effects of fluorodeoxyglucose: Global changes in the lipidome and alteration in intracellular transport. <i>Oncotarget</i> , <b>2016</b> , 7, 79885-79900	3.3	4
30	The anti-tumor drug 2-hydroxyoleic acid (Minerval) stimulates signaling and retrograde transport. <i>Oncotarget</i> , <b>2016</b> , 7, 86871-86888	3.3	14
29	Determining the Turnover of Glycosphingolipid Species by Stable-Isotope Tracer Lipidomics. <i>Journal of Molecular Biology</i> , <b>2016</b> , 428, 4856-4866	6.5	25
28	Data including GROMACS input files for atomistic molecular dynamics simulations of mixed, asymmetric bilayers including molecular topologies, equilibrated structures, and force field for lipids compatible with OPLS-AA parameters. <i>Data in Brief</i> , <b>2016</b> , 7, 1171-1174	1.2	15
27	The ether lipid precursor hexadecylglycerol stimulates the release and changes the composition of exosomes derived from PC-3 cells. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 4225-37	5.4	65
26	Different roles of the C-terminal end of Stx1A and Stx2A for AB5 complex integrity and retrograde transport of Stx in HeLa cells. <i>Pathogens and Disease</i> , <b>2015</b> , 73, ftv083	4.2	2
25	Novel actions of 2-deoxy-D-glucose: protection against Shiga toxins and changes in cellular lipids. <i>Biochemical Journal</i> , <b>2015</b> , 470, 23-37	3.8	12
24	Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo. <i>Molecules</i> , <b>2015</b> , 20, 13313-23	4.8	42
23	Identification of prostate cancer biomarkers in urinary exosomes. <i>Oncotarget</i> , <b>2015</b> , 6, 30357-76	3.3	138
23	Identification of prostate cancer biomarkers in urinary exosomes. <i>Oncotarget</i> , <b>2015</b> , 6, 30357-76  Shiga toxins <b>2015</b> , 267-286	3.3	138
		3.3	
22	Shiga toxins <b>2015</b> , 267-286		1
22	Shiga toxins <b>2015</b> , 267-286  Lipid requirements for entry of protein toxins into cells. <i>Progress in Lipid Research</i> , <b>2014</b> , 54, 1-13	14.3	1 62
22 21 20	Shiga toxins <b>2015</b> , 267-286  Lipid requirements for entry of protein toxins into cells. <i>Progress in Lipid Research</i> , <b>2014</b> , 54, 1-13  Development of nanoparticles for clinical use. <i>Nanomedicine</i> , <b>2014</b> , 9, 1295-9  The ether lipid precursor hexadecylglycerol protects against Shiga toxins. <i>Cellular and Molecular</i>	14.3 5.6	1 62 25
22 21 20	Shiga toxins <b>2015</b> , 267-286  Lipid requirements for entry of protein toxins into cells. <i>Progress in Lipid Research</i> , <b>2014</b> , 54, 1-13  Development of nanoparticles for clinical use. <i>Nanomedicine</i> , <b>2014</b> , 9, 1295-9  The ether lipid precursor hexadecylglycerol protects against Shiga toxins. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 4285-300  Cell density-induced changes in lipid composition and intracellular trafficking. <i>Cellular and</i>	14.3 5.6 10.3	1 62 25 12
22 21 20 19	Shiga toxins <b>2015</b> , 267-286  Lipid requirements for entry of protein toxins into cells. <i>Progress in Lipid Research</i> , <b>2014</b> , 54, 1-13  Development of nanoparticles for clinical use. <i>Nanomedicine</i> , <b>2014</b> , 9, 1295-9  The ether lipid precursor hexadecylglycerol protects against Shiga toxins. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 4285-300  Cell density-induced changes in lipid composition and intracellular trafficking. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 1097-116  Retrograde transport of protein toxins through the Golgi apparatus. <i>Histochemistry and Cell Biology</i>	14.3 5.6 10.3	1 62 25 12 32

## LIST OF PUBLICATIONS

Molecular imaging: challenges of bringing imaging of intracellular targets into common clinical use. <i>Contrast Media and Molecular Imaging</i> , <b>2012</b> , 7, 1-6	3.2	45
Shiga toxins. <i>Toxicon</i> , <b>2012</b> , 60, 1085-107	2.8	140
Shiga toxin and its use in targeted cancer therapy and imaging. <i>Microbial Biotechnology</i> , <b>2011</b> , 4, 32-46	6.3	81
Clathrin-independent endocytosis: mechanisms and function. <i>Current Opinion in Cell Biology</i> , <b>2011</b> , 23, 413-20	9	184
Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. <i>Nano Today</i> , <b>2011</b> , 6, 176-185	17.9	930
Changes of protein solutions during storage: a study of albumin pharmaceutical preparations. <i>Biotechnology and Applied Biochemistry</i> , <b>2010</b> , 55, 121-30	2.8	6
Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. <i>FEBS Letters</i> , <b>2010</b> , 584, 2626-34	3.8	97
New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2010</b> , 6, 730-7	6	53
Whole-body section fluorescence imaginga novel method for tissue distribution studies of fluorescent substances. <i>Contrast Media and Molecular Imaging</i> , <b>2009</b> , 4, 73-80	3.2	6
Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. <i>Traffic</i> , <b>2009</b> , 10, 868-8	B <b>2</b> 5.7	51
NC100668, a new tracer tested for imaging of venous thromboembolism: pharmacokinetics and metabolism in humans. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 1979-84	4	5
Nc100668, a new tracer for imaging of venous thromboembolism: disposition and metabolism in rats. <i>Drug Metabolism and Disposition</i> , <b>2006</b> , 34, 111-20	4	13
In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2002</b> , 28, 323-9	3.5	66
	Contrast Media and Molecular Imaging, 2012, 7, 1-6  Shiga toxins. Toxicon, 2012, 60, 1085-107  Shiga toxin and its use in targeted cancer therapy and imaging. Microbial Biotechnology, 2011, 4, 32-46  Clathrin-independent endocytosis: mechanisms and function. Current Opinion in Cell Biology, 2011, 23, 413-20  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today, 2011, 6, 176-185  Changes of protein solutions during storage: a study of albumin pharmaceutical preparations. Biotechnology and Applied Biochemistry, 2010, 55, 121-30  Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Letters, 2010, 584, 2626-34  New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 730-7  Whole-body section fluorescence imaging—a novel method for tissue distribution studies of fluorescent substances. Contrast Media and Molecular Imaging, 2009, 4, 73-80  Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. Traffic, 2009, 10, 868-00.  NC100668, a new tracer tested for imaging of venous thromboembolism: pharmacokinetics and metabolism in humans. Drug Metabolism and Disposition, 2007, 35, 1979-84  Nc100668, a new tracer for imaging of venous thromboembolism: disposition and metabolism in rats. Drug Metabolism and Disposition, 2006, 34, 111-20  In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. Journal of Pharmaceutical and Biomedical Analysis,	Shiga toxins. Toxican, 2012, 60, 1085-107  2.8  Shiga toxin and its use in targeted cancer therapy and imaging. Microbial Biotechnology, 2011, 4, 32-46  Glathrin-independent endocytosis: mechanisms and function. Current Opinion in Cell Biology, 2011, 23, 413-20  Endocytosis and intracellular transport of nanoparticles: Present knowledge and need for future studies. Nano Today, 2011, 6, 176-185  Changes of protein solutions during storage: a study of albumin pharmaceutical preparations. Biotechnology and Applied Biochemistry, 2010, 55, 121-30  Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Letters, 2010, 584, 2626-34  New metal-based nanoparticles for intravenous use: requirements for clinical success with focus on medical imaging. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 730-7  Whole-body section fluorescence imaging—a novel method for tissue distribution studies of fluorescent substances. Contrast Media and Molecular Imaging, 2009, 4, 73-80  Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. Traffic, 2009, 10, 868-82-7  NC100668, a new tracer tested for imaging of venous thromboembolism: pharmacokinetics and metabolism in humans. Drug Metabolism and Disposition, 2007, 35, 1979-84  Ac100668, a new tracer for imaging of venous thromboembolism: disposition and metabolism in rats. Drug Metabolism and Disposition, 2006, 34, 111-20  In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging. Journal of Pharmaceutical and Biomedical Analysis, 3-5